Home » Stocks » Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd

The live share price of Sun Pharmaceutical Industries Ltd (SUNPHARMA) as on 30 May 10:26am is ₹959.6 from NSE/BSE.

SUNPHARMA NSE

₹959.6 ▼-0.91% (-8.85)

As on May 30, 2023 03:56 PM IST

How do you feel today about Sun Pharmaceutical Industries Ltd?

Key Metrics

PE Ratio

27.27

PB Ratio

4.55

Dividend Yield

1.19%

Sector PB

4.49

Sector PE

33.72

Sector Div Yld

0.82%

Dividend Yield

Dividend per share for the most recent financial year divided by the close price

About

sec-img

Sector

Health Care

sec-img

Industry

Pharmaceuticals

sec-img

Market Cap

Largecap, ₹2,32,363 Cr

Sun Pharmaceutical Industries Limited is a pharmaceuticals company which offers generics, branded generics, specialty products, over-the-counter products, anti-retroviral and APIs.

The following charts display the financial performance of the Sun Pharmaceutical Industries Ltd (SUNPHARMA) stock, including the year-on-year Income Statement , Balance Sheet , Cash Flow Statement and Shareholding pattern.

Furthermore, under the Peers section, you can find stocks that are similar to Sun Pharmaceutical Industries Ltd (SUNPHARMA), and their live stock price and performance at a glance. Click on any peer stock to navigate to that stock’s live price page.

✅ If you’re new to investing in the stock market, and/or are unsure about your investment options, you can explore smallcases.

A smallcase is a readymade stock/ETF portfolio (also known as a stock basket) that is based on an investment idea, theme or strategy. Examples of popular smallcases include All Weather Investing , Equity and Gold , Top 100 Stocks , Green Energy and Value & Momentum.

All smallcases are created and managed by SEBI-registered investment experts.

To invest in smallcases, all you need is a demat/trading account. You retain complete ownership of the smallcase’s constituent stocks or ETFs, as they are directly credited to your broking account. You can choose from over 500+ smallcases across 180+ smallcase managers to start your investment journey.

sec-img

Sector

Health Care

sec-img

Industry

Pharmaceuticals

sec-img

Market Cap

Largecap, ₹2,32,363 Cr

Financials

Income Statement

(INR) Y/Y Change
Revenue 44,520 Cr +12.06%
Operating Expense 32,410 Cr +352.08%
Net Income 8,521 Cr +160.38%
Net Profit Margin 19.14% +132.28%
Earning Per Share 35 +158.79%
EBITDA 12,109 Cr +79.34%

Balance sheet

(INR) Y/Y Change
Cash & short-term Inv 12,667 Cr +32.29%
Total Assets 69,768 Cr +3.17%
Total Liabilities 18,701 Cr +3.08%
Total Equity 51,066 Cr +3.21%
Shares Outstanding 239.93 Cr -
Price to Book 4.27 +44.18%
Return on Assets 4.76% +11.21%
Return on Capital 9.02 Cr +51.85%

Cash Flows

(INR) Y/Y Change
Net Income 8,521 Cr +160.38%
Cash from Operations 8,984 Cr +45.61%
Cash from Investing -5,555 Cr -1466.65%
Cash from Financing -5,193 Cr -13.16%
Net Change in Cash -1,764 Cr -395.9%
Free Cash Flow 7,489 Cr +49.78%
Total Promoter Holding
54.48%
Unpledged
Foreign Institutions
16.89%
Foreign Institutions
Retail & Others
9.39%
Retail & Others
Other Parties
Other Domestic Institutions
6.34%
Insurance Firms
Others
Mutual Funds
12.91%
Mutual Funds

Peers

CIPLA

Cipla Ltd

PE Ratio

27.52

1Y Return

▼-2.73%

DRREDDY

Dr Reddy's Laboratories Ltd

PE Ratio

16.8

1Y Return

▲3.4%

TORNTPHARM

Torrent Pharmaceuticals Ltd

PE Ratio

69.48

1Y Return

▲18.78%

MANKIND

Mankind Pharma Ltd

PE Ratio

0

1Y Return

▼-4.67%

Latest News

latest-news

Stocks to watch: Adani Ports, NMDC, HDFC Life, Apollo Hospitals, PTC Inds

1 hour ago on Business Standard

Change since news 0%

Stocks to watch on May 31, 2023: From Adani Ports to Sun Pharma, here are top stocks to watch in Wednesday’s trading session


latest-news

‘Sun Pharma eyes deals to push specialty play, EM business’

9 hours ago on Economic Times

Change since news 0%

Sun Pharma, India’s largest drugmaker, is looking at acquisitions to boost its specialty pipeline and strengthen emerging markets business. “Our focus on M&A will be on augmenting the pipeline for specialty and further strengthening our footprint in emerging markets,” said CS Muralidharan, chief fin…


latest-news

Sun Pharmaceutical Gets China NMPA Approval For Plaque Psoriasis

13 hours ago on Bloomberg Quint

Change since news ▲0.91%

The product under the brand name Ilumetri has been approved by China’s National Medical Products Administration.


latest-news

Sun Pharma receives China NMPA’s nod for treatment of plaque psoriasis

13 hours ago on Business Standard

Change since news ▲0.91%

Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy


latest-news

Will work with Taro-appointed committee for “win-win” transaction for both: Sun Pharma CFO

14 hours ago on The Hindu Businessline

Change since news ▲0.91%

Sun’s CFO explained getting full control of Taro would enable, among other things, the delisting of the company from NYSE


latest-news

Stock market update: Stocks that hit 52-week lows on NSE in today’s trade

15 hours ago on Economic Times

Change since news ▲0.91%

Hindalco, Adani Ent., Tech Mahindra, Tata Steel and Sun Pharma were among the top losers on NSE in today’s trade.


latest-news

Sensex, Nifty rise for 4th straight session

16 hours ago on Economic Times

Change since news ▲0.91%

From the Sensex pack, ITC, Bajaj Finserv, Kotak Bank, and Bajaj Finance were the top gainers, rising 1-2%. Axis Bank, HCL Tech, Wipro, UltraTech Cement, and Maruti also closed with gains. On the flip side, Tata Steel, Tech Mahindra, Sun Pharma, Nestle, L&T, and SBI closed with losses.


latest-news

Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe

18 hours ago on Business Standard

Change since news ▲0.91%

Sun Pharmaceutical Industries on Tuesday said it has entered into a licensing pact with Philogen SpA to commercialise under-development skin cancer drug in Europe, Australia and New Zealand.


latest-news

Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand

18 hours ago on Economic Times

Change since news ▲0.91%

Sun Pharmaceutical Industries on Tuesday said it has entered into a licensing pact with Philogen SpA to commercialise under-development skin cancer drug in Europe, Australia and New Zealand. The companies have come together to commercialise Philogen’s speciality product Nidlegy, an anti-cancer bioph…


latest-news

Sun Pharma Q4 Results Review - US/EM/ROW Drive Earnings For The Quarter: Motilal Oswal

19 hours ago on Bloomberg Quint

Change since news ▲0.91%

Sun Pharma Q4 Results Review - US/EM/ROW Drive Earnings For The Quarter: Motilal Oswal


FAQs on Sun Pharmaceutical Industries Ltd

How to buy Sun Pharmaceutical Industries Ltd stocks?

You can easily buy the stocks/shares of Sun Pharmaceutical Industries Ltd (SUNPHARMA) through either a broker or a financial institution by opening a Demat & Trading account online via smallcase.

What is the Share Price of Sun Pharmaceutical Industries Ltd?

The stock price of Sun Pharmaceutical Industries Ltd as on 30 May 2023 is ₹959.6

What is the 52-week High and Low of Sun Pharmaceutical Industries Ltd?

The 52-week high and low of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹1,072.15 and ₹789.9.

What is the PE and PB ratio of Sun Pharmaceutical Industries Ltd?

The P/E (price-to-earnings) and P/B (price-to-book) ratios of Sun Pharmaceutical Industries Ltd are 27.27 and 4.55 respectively.

What are the peers or stocks similar to Sun Pharmaceutical Industries Ltd?

The peers or stocks similar to Sun Pharmaceutical Industries Ltd are Cipla Ltd, Dr Reddy's Laboratories Ltd, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd and many others. smallcase also offers over 200 readymade stock baskets managed by 180+ SEBI-registered investment experts. These stock portfolios are based on a theme, idea or strategy. You can use smallcase to start investing in diversified stock baskets.

Which sector does Sun Pharmaceutical Industries Ltd belong to?

Sun Pharmaceutical Industries Ltd (SUNPHARMA) belongs to the Pharmaceuticals sector.

What is the Market Cap of Sun Pharmaceutical Industries Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹2,32,363 Cr as of 30 May 2023

Can't decide whether or not to buy Sun Pharmaceutical Industries Ltd stocks? ⭐️

Worry no more! smallcase offers readymade stock baskets/portfolios that are based on an theme, idea or strategy. You can choose from more than 500+ stock portfolios managed by 180+ SEBI-registered investment experts.